|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0017387,
umls-concept:C0019168,
umls-concept:C0032868,
umls-concept:C0042211,
umls-concept:C0042216,
umls-concept:C0205460,
umls-concept:C0206558,
umls-concept:C0441513,
umls-concept:C0441655,
umls-concept:C1514798,
umls-concept:C1527177,
umls-concept:C1824884,
umls-concept:C2608085
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
1984-3-1
|
|
pubmed:abstractText |
Potential live vaccines using recombinant vaccinia viruses have been constructed for both hepatitis B and herpes simplex. These recombinant vaccinia viruses express cloned genes of the hepatitis B virus surface antigen (HBsAg) or the glycoprotein D from herpes simplex virus (HSV-gD). The HBsAg synthesized in vitro under the regulation of vaccinia virus is secreted from infected cells as a particle of approximately equal to 22 nm diameter with a density of 1.2 g/ml as determined on CsCl gradients. Inoculation of rabbits with the recombinant vaccinia virus that expresses the HBsAg elicits the production of high-titered antibodies. Synthesis of the HSV-gD was detected in tissue culture by radioimmunoassay on unfixed cells, suggesting that the HSV-gD synthesized by the recombinant vaccinia virus is membrane associated. Inoculation of rabbits with the recombinant vaccinia virus expressing HSV-gD resulted in the production of antibodies that reacted with authentic HSV-gD as detected by radioimmunoassay. Furthermore, the anti-serum was shown by plaque-reduction assay to neutralize the infectivity of herpes simplex virus. Immunization of mice with the vaccinia recombinant expressing HSV-gD gave complete protection on subsequent challenge with lethal doses of live herpes simplex virus.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/6320164-171586,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6320164-187208,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6320164-219254,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6320164-334041,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6320164-399327,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6320164-5105002,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6320164-6159137,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6320164-6254085,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6320164-6262520,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6320164-6264599,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6320164-6280173,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6320164-6287015,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6320164-6289324,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6320164-6289440,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6320164-6296831,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6320164-6310573,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6320164-63998,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6320164-645175,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6320164-6835382,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6320164-6951197,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6320164-6952231,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6320164-6997970,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6320164-7086959,
http://linkedlifedata.com/resource/pubmed/commentcorrection/6320164-92575
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0027-8424
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
81
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
193-7
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:6320164-Animals,
pubmed-meshheading:6320164-Antibody Formation,
pubmed-meshheading:6320164-Chimera,
pubmed-meshheading:6320164-Cloning, Molecular,
pubmed-meshheading:6320164-DNA, Recombinant,
pubmed-meshheading:6320164-DNA Restriction Enzymes,
pubmed-meshheading:6320164-Genes,
pubmed-meshheading:6320164-Genes, Viral,
pubmed-meshheading:6320164-Genetic Engineering,
pubmed-meshheading:6320164-Hepatitis B Surface Antigens,
pubmed-meshheading:6320164-Hepatitis B virus,
pubmed-meshheading:6320164-Plasmids,
pubmed-meshheading:6320164-Rabbits,
pubmed-meshheading:6320164-Simplexvirus,
pubmed-meshheading:6320164-Vaccinia virus,
pubmed-meshheading:6320164-Viral Envelope Proteins,
pubmed-meshheading:6320164-Viral Proteins,
pubmed-meshheading:6320164-Viral Vaccines
|
|
pubmed:year |
1984
|
|
pubmed:articleTitle |
Construction of live vaccines using genetically engineered poxviruses: biological activity of vaccinia virus recombinants expressing the hepatitis B virus surface antigen and the herpes simplex virus glycoprotein D.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.
|
